Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > VMS+ tech. and its unique contributions to advancing cardiac
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(91)
•••
Comment by jopatcloon Jun 24, 2024 10:11am
20 Views
Post# 36103111

RE:VMS+ tech. and its unique contributions to advancing cardiac

RE:VMS+ tech. and its unique contributions to advancing cardiacGood comment on Linkedin 
Sharing an article on how AI may impact the healthcare industry specifically for loved ones with chronic heart disease. Ventripoint Diagnostics provides faster, less expensive and cMRI levels of accuracy for all four chambers of the heart (ventricle volumes & ejection fractions). AI enhanced echo is a more patient-friendly (children & elders) modality which improves efficiency and reduces risk.

If you are an investor and interested in the company send me a message.
In this article, we explore the transformative potential of Artificial Intelligence (AI) in clinical trials, highlighting its current challenges in daily clinical practice and showcasing how AI is revolutionizing the field of cardiology. We will delve into the specific advantages AI offers in improving efficiency, accuracy, and outcomes in clinical trials, with a special focus on Ventripoint's VMS+ technology and its unique contributions to advancing cardiac research.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities